119 HR 4993 IH: Joe Fiandra Access to Home Infusion Act of 2025 U.S. House of Representatives 2025-08-19 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I119th CONGRESS1st SessionH. R. 4993IN THE HOUSE OF REPRESENTATIVESAugust 19, 2025Mr. Fitzpatrick (for himself, Mr. Dunn of Florida, and Mr. Soto) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concernedA BILLTo amend title XVIII of the Social Security Act to provide coverage of external infusion pumps and non-self-administrable home infusion drugs under the Medicare program.

1.

Short title

This Act may be cited as the Joe Fiandra Access to Home Infusion Act of 2025.

2.

Medicare coverage of external infusion pumps and non-self-administrable home infusion drugs

(a)

In general

Section 1861(n) of the Social Security Act (42 U.S.C. 1395x(n)) is amended by adding at the end the following new sentence: Beginning with the first calendar quarter beginning on or after the date that is 1 year after the date of the enactment of this sentence, an external infusion pump and associated home infusion drug (as defined in subsection (iii)(3)(C)) or other associated supplies that do not meet the appropriate for use in the home requirement applied to the definition of durable medical equipment under section 414.202 of title 42, Code of Federal Regulations (or any successor to such regulation) shall be treated as meeting such requirement if each of the following criteria is satisfied: (1)The prescribing information approved by the Food and Drug Administration for the home infusion drug associated with the pump instructs that the drug should be administered by or under the supervision of a health care professional. (2)A qualified home infusion therapy supplier (as defined in subsection (iii)(3)(D)) administers or supervises the administration of the drug or biological in a safe and effective manner in the patient’s home (as defined in subsection (iii)(3)(B)). (3)The prescribing information described in paragraph (1) instructs that the drug should be infused at least 12 times per year— (A)intravenously or subcutaneously; or (B)at infusion rates that the Secretary determines would require the use of an external infusion pump.. (b)

Cost sharing notification

The Secretary of Health and Human Services shall ensure that patients are notified of the cost sharing for electing home infusion therapy compared to other applicable settings of care for the furnishing of infusion drugs under the Medicare program.